Cesium chloride- and iodixanol-based density gradients represent the core step in most protocols for serotype-independent adeno-associated virus (AAV) purification. However, despite controversial reports about purity and bioactivity of AAV vectors derived from each of these protocols, systematic comparisons of variants of these methods are sparse. Strobel and colleagues from Boehringer Ingelheim Pharma recently carried out a study, published in Human Gene Therapy Methods, illustrating that iodixanol-purified AAV preparations show higher vector purity but harbor more (~20%) empty particles as compared to CsCl-purified vectors (<1%). Using mass spectrometry, the team analyzed prominent protein impurities in the AAV vector product, thereby identifying known and new possibly AAV-interacting proteins as major contaminants.
Purification of Recombinant AAV Vectors for Preclinical Applications
Akoya Biosciences offers single-cell imaging solutions that enable researchers to phenotype cells with spatial context and visualize how they organize and interact. These solutions include the PhenoImager-Fusion, an imaging platform; the PhenoCycler, a fluidics cycling instrument; and the PhenoImager HT, a platform for the discovery of spatial signatures at scale. Akoya also offers an integrated solution called the PhenoCycler-Fusion. It is designed to allow researchers to map a million cells in as little as 10 minutes. It produced this image from a human FFPE sample consisting of more than 3 million cells.
